Jasdeep S. Kler

Jasdeep S. Kler

Auto-generated profile, based on publicly available information

Jasdeep S. Kler

Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2019 in Nature Sustainability
Verified
Journal Article
Closed access
PDF file
TJTyler A. Jacobson
Tyler A. Jacobson
JKJasdeep S. Kler
Jasdeep S. Kler
MHMichael T. Hernke
Michael T. Hernke
RBRudolf K. Braun
Rudolf K. Braun
KMKeith C. Meyer
Keith C. Meyer
WFWilliam E. Funk
William E. Funk

1 July 2018 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ZMZachary S. Morris
Zachary S. Morris
EGEmily I. Guy
Emily I. Guy
LWLauryn R. Werner
Lauryn R. Werner
PCPeter M. Carlson
Peter M. Carlson
CHClinton M. Heinze
Clinton M. Heinze
PSPaul M. Sondel
Paul M. Sondel
In situ vaccination is an emerging cancer treatment strategy that uses local therapies to stimulate a systemic antitumor immune response. We previously reported an in situ vaccination effect when combining radiation (RT) with intratumor (IT) injection of tumor-specific immunocytokine (IC), a fusion of tumor-specific antibody and IL2 cytokine. In mice bearing two tumors, we initially hypothesized that delivering RT plus IT-IC to the “primary” tumor would induce a systemic antitumor response causing regression of the “secondary” tumor. To test this, mice bearing one or two syngeneic murine tumors of B78 melanoma and/or Panc02 pancreatic cancer were treated with combined external beam RT and IT-IC to the designated “primary” tumor only. Primary and secondary tumor response as well as animal survival were monitored. Immunohistochemistry and quantitative real-time PCR were used to quantify tumor infiltration with regulatory T cells (Treg). Transgenic “DEREG” mice or IgG2a anti–CTLA-4 were used to transiently deplete tumor Tregs. Contrary to our initial hypothesis, we observed that the presence of an untreated secondary tumor antagonized the therapeutic effect of RT + IT-IC delivered to the primary tumor. We observed reciprocal tumor specificity for this effect, which was circumvented if all tumors received RT or by transient depletion of Tregs. Primary tumor treatment with RT + IT-IC together with systemic administration of Treg-depleting anti–CTLA-4 resulted in a renewed in situ vaccination effect. Our findings show that untreated tumors can exert a tumor-specific, Treg-dependent, suppressive effect on the efficacy of in situ vaccination and demonstrate clinically viable approaches to overcome this effect. Untreated tumor sites antagonize the systemic and local antitumor immune response to an in situ vaccination regimen. This effect is radiation sensitive and may be mediated by tumor-specific regulatory T cells harbored in the untreated tumor sites. Cancer Immunol Res; 6(7); 825–34. ©2018 AACR.

4 November 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
MMMegan A. Mullins
Megan A. Mullins
JKJasdeep S. Kler
Jasdeep S. Kler
MEMarisa R. Eastman
Marisa R. Eastman
MKMohammed Kabeto
Mohammed Kabeto
LWLauren P. Wallner
Lauren P. Wallner
LKLindsay Kobayashi
Lindsay Kobayashi
Background: The US Health Retirement Study (HRS) is an ongoing population-representative cohort of US adults ages >50 with rich data on health during aging. Self-reported cancer diagnoses have been collected since 1998, but they have not been validated. We compared self-reported cancer diagnoses in HRS interviews against diagnostic claims from linked Medicare records. Methods: Using HRS–Medicare linked data, we examined the validity of first incident cancer diagnoses self-reported in biennial interviews from 2000 to 2016 against ICD-9 and ICD-10 diagnostic claim records as the gold standard. Data were from 8,242 HRS participants ages ≥65 with 90% continuous enrollment in fee-for-service Medicare. We calculated the sensitivity, specificity, and κ for first incident invasive cancer diagnoses (all cancers combined, and each of bladder, breast, colorectal/anal, uterine, kidney, lung, and prostate cancers) cumulatively over the follow-up and at each biennial study interview. Results: Overall, self-reports of first incident cancer diagnoses from 2000 to 2016 had 73.2% sensitivity and 96.2% specificity against Medicare claims (κ = 0.73). For specific cancer types, sensitivities ranged from 44.7% (kidney) to 75.0% (breast), and specificities ranged from 99.2% (prostate) and 99.9% (bladder, uterine, and kidney). Results were similar in sensitivity analyses restricted to individuals with 100% continuous fee-for-service Medicare enrollment and when restricted to individuals with at least 24 months of Medicare enrollment. Conclusions: Self-reported cancer diagnoses in the HRS have reasonable validity for use in population-based research that is maximized with linkage to Medicare. Impact: These findings inform the use of the HRS for population-based cancer and aging research.

1 September 2017 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LWLauryn R. Werner
Lauryn R. Werner
JKJasdeep S. Kler
Jasdeep S. Kler
MGMonica M. Gressett
Monica M. Gressett
MRMaureen Riegert
Maureen Riegert
LWLindsey K. Werner
Lindsey K. Werner
ZMZachary S. Morris
Zachary S. Morris

1 December 2025 in Tracheostomy: Official Journal of the Global Tracheostomy Collaborative
Verified
Journal Article
Open access
PDF file
NLNicholas R Lenze
Nicholas R Lenze
JKJasdeep S Kler
Jasdeep S Kler
CPChamila D Perera
Chamila D Perera
KCKaran R Chhabra
Karan R Chhabra
DGDavid Goldenberg
David Goldenberg
Michael J. BrennerMichael J. Brenner
Michael J. Brenner
Introduction: Tracheostomy involves complex, resource-intensive care. Yet, few data about the procedure-related cost burden for patients and their families are available. Passage of the No Surprises Act has been associated with changes in patient billing for certain healthcare services, but data on tracheostomy have not been investigated. Methods: We conducted a retrospective cohort study using the Merative MarketScan database for commercially insured patients aged 18-64 who underwent tracheostomy from 2014-2022 in the United States. We estimated out-of-pocket (OOP) costs (sum of deductibles, copay, and coinsurance) and potential surprise bills (an out-of-network claim where both the primary surgeon and facility were in-network) within 30 days of surgery. Relationships between OOP costs, potential surprise bills, and patient- and system-level exposures were analyzed. Results: Among 8,950 patients who underwent tracheostomy, the mean (SD) age was 49.3 (12.7) years; most patients were male (61.8%) and had fee-for-service based insurance (79.8%). The mean (SD) total OOP cost attributable to tracheostomy was $1,423 (2,029), and coinsurance accounted for 62.8% of these costs. Potential surprise bills were present in 9.1% of surgical episodes overall and were associated with higher OOP costs (mean (SD) $1909 (2433) vs. $1444 (2021); p<0.001)). High-deductible health plans and fee-for-service based plans were the largest predictors for overall OOP costs (cost ratio 2.66 and 1.84, respectively; p<0.001 for both) and potential surprise bills (odds ratio 2.07 and 2.78, respectively; p<0.001 for both). The incidence of potential surprise bills diminished over the course of the study period. Conclusions: Patients undergoing tracheostomy have significant exposure to OOP costs, predominantly attributable to coinsurance, with potential surprise bills representing an additional source of cost exposure. These findings highlight the need for financial counseling and policy reform to reduce patient cost burdens.

17 December 2025
Verified
Other
Open access
MMMegan A. Mullins
Megan A. Mullins
JKJasdeep S. Kler
Jasdeep S. Kler
MEMarisa R. Eastman
Marisa R. Eastman
MKMohammed Kabeto
Mohammed Kabeto
LWLauren P. Wallner
Lauren P. Wallner
LKLindsay Kobayashi
Lindsay Kobayashi
Age Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016